Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript Summary
Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript Summary
Net loss decreased by 57%; Operating expenses down 34% to $2.8 million.The following is a summary of the Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript:
以下是Biotricity, Inc. (BTCY) 2025年第二季度業績會交易摘要：
Financial Performance:
財務表現：
Revenue increased to $3.3 million, up 13%; Gross profit grew to $2.5 million, up 23%.
Net loss decreased by 57%; Operating expenses down 34% to $2.8 million.
營業收入增至$330萬，增長13%; 毛利潤增至$250萬，增長23%。
淨虧損減少了57%; 營業費用下降34%至$280萬。
Business Progress:
業務進展：
Achieved positive EBITDA for the first time; planning FDA approval for AI clinical model.
Launched next generation Biocore Pro; expanded market reach through new strategic alliances.
首次實現正面EBITDA; 計劃獲得人工智能臨床模型的FDA批准。
推出下一代Biocore Pro; 通過新的戰略聯盟擴大市場覆蓋範圍。
Opportunity:
機會：
Partnerships with top GPOs and expansion into new medical fields present larger market opportunities.
Regulatory approvals and AI capabilities integration enhance patient outcomes and operational efficiencies.
與頂級GPO合作，擴展到新的醫療領域，提供更大的市場機遇。
監管批准和人工智能能力整合，提高患者結果和運營效率。
Risk:
風險：
Managing inventory effectively to meet demand without overextending resources poses a challenge.
Large inventory investments carry risks if market demand fluctuates.
有效管理庫存以滿足需求，而不會過度使用資源，面臨挑戰。
如果市場需求波動，大量庫存投資存在風險。
Financial Performance:
財務表現：
Biotricity reported a revenue increase of 13% in Q2 2025 to $3.3 million.
Gross profit grew 23% to $2.5 million, with a gross profit margin enhancement to 75.3% from 73.8% last year.
Net loss decreased significantly by 57% to $1.65 million, showing progress towards financial stability.
Recurring revenue remains robust, driven by strong demand for their FDA-cleared cardiac monitoring devices, notably the Biocore line.
Operating expenses were down by 34% to $2.8 million due to streamlined operations and reduced R&D costs.
EBITDA for the three-month period improved by 80%, with an 87% improvement in adjusted EBITDA, reflecting near breakeven levels.
Biotricity在2025年第二季度報告營業收入增長13%，達到330萬美元。
毛利潤增長23%，達到250萬美元，毛利率從去年的73.8%提升至75.3%。
淨虧損顯著減少了57%至165萬美元，顯示朝着財務穩定的進展。
經常性收入保持強勁增長，受到其獲得FDA認可的心臟監測設備需求旺盛的推動，尤其是Biocore產品線。
由於精簡運營和降低研發成本，營業費用下降了34%至280萬美元。
三個月的EBITDA得到了80%的改善，調整後的EBITDA較去年同期提高了87%，反映出接近盈虧平衡水平。
Business Progress:
業務進展：
Biotricity marked a transformative quarter with a shift to positive EBITDA and continued strides towards profitability.
Published research on predicting postoperative complications and plans to file for FDA approval of their AI clinical model by mid-next-year.
Expanded market reach through new strategic alliances with top GPOs and specialist organizations beyond cardiology.
Launched the next generation Biocore Pro, enhancing their technology portfolio.
Anticipate continued growth and improvements in revenue and client base, along with advancing the commercialization of Biocore and Biocare products globally.
Biotricity標誌着一個變革性的季度，實現了盈利EBITDA並持續朝着盈利能力邁進。
發表了關於預測術後併發症的研究，並計劃在明年年中申請他們的AI臨床模型獲得FDA批准。
通過與頂尖集團採購組織和專業機構的新戰略聯盟，擴大了市場覆蓋範圍，超越了心臟病領域。
推出了下一代Biocore Pro，增強了其技術組合。
預計持續增長和營業收入和客戶群體的改善，以及全球Biocore和Biocare產品的商業化進展。
Opportunities:
機會：
The partnerships with the top GPOs and expansion into neurology and pulmonology open larger market opportunities and potential for securing bigger contracts.
Regulatory approvals, like the one from Health Canada, expand their operational territories and market scope.
The focus on integrating AI capabilities for predictive diagnostics presents significant opportunities in enhancing patient outcomes and operational efficiencies.
與頂尖GPO合作伙伴關係並拓展到神經學和肺病學領域，爲獲得更大的市場機會和更大合同的潛力打開了可能性。
像加拿大衛生部的那次監管批准一樣，擴大了其運營領域和市場範圍。
專注於整合人工智能能力進行預測診斷，爲提高患者結果和運營效率提供重要機會。
Risks:
風險：
The ongoing requirement to manage inventory effectively to meet the demands of new and transitioning existing customers without overextending company resources.
Challenges associated with large inventory investments, which while supportive of growth, pose risks if market demand fluctuates unexpectedly.
持續管理庫存以有效滿足新客戶和轉移現有客戶需求的要求，而不過度消耗公司資源。
大量庫存投資所帶來的挑戰，雖然支持增長，但如果市場需求出現意外波動，可能會帶來風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
